LABD is an autoimmune subepidermal bullous disease which is characterized by linear deposition of immunoglobulin (Ig) in the basement membrane. The definite pathogenesis of LABD is still unknown. Some cases of LABD have been associated with drugs. Vancomycin is the most commonly implicated drug. Although LABD is a relatively rare adverse reaction of vancomycin, it is important for clinicians to be aware of this reaction because the use of vancomycin is increasing along with the increase in the incidence of MRSA infections.
Basement Membrane ; Humans ; Immunoglobulins ; Incidence ; Linear IgA Bullous Dermatosis* ; Methicillin-Resistant Staphylococcus aureus ; Uterine Cervical Neoplasms* ; Vancomycin

LABD is an autoimmune subepidermal bullous disease which is characterized by linear deposition of immunoglobulin (Ig) in the basement membrane. The definite pathogenesis of LABD is still unknown. Some cases of LABD have been associated with drugs. Vancomycin is the most commonly implicated drug. Although LABD is a relatively rare adverse reaction of vancomycin, it is important for clinicians to be aware of this reaction because the use of vancomycin is increasing along with the increase in the incidence of MRSA infections.
Basement Membrane ; Humans ; Immunoglobulins ; Incidence ; Linear IgA Bullous Dermatosis* ; Methicillin-Resistant Staphylococcus aureus ; Uterine Cervical Neoplasms* ; Vancomycin

PURPOSE: The aim of this study was to longitudinally examine the correlation between the change of atopic dermatitis (AD) severity and the change of quality of life (QOL). METHODS: We assessed AD severity and QOL of patients and their families, by a prospective followed up for at least 12 months. AD severity was assessed, using the scoring of atopic dermatitis (SCORAD) index. A questionnaire based on dermatitis family impact (DFI), infants' dermatologic quality of life (IDQoL) and children's dermatology life quality index (CDLQI) were used to determine QOL. RESULTS: Seventy-nine AD patients were assessed for total and objective SCORAD and DFI. Among them, 45 patients that were less than 36 months old completed IDQoL and 13 patients that were equal to or more than 36 months old completed CDLQI. Objective SCORAD (oSCORAD) were correlated with DFI (r=0.235), IDQoL (r=0.602) and CDLQI (r=0.589) (P<0.05). At the 2nd interview, median oSCORAD (from 17.4 to 7.8), DFI (from 23.0 to 18.0) and IDQoL (from 9.0 to 6.0) were significantly decreased (P<0.01). The changes of oSCORAD were linearly related with the change of IDQoL (P<0.01), but neither with DFI (P=0.356) nor with CDLQI (P=0.267). Of the 64 patients with decreased oSCORAD, food allergy was accompanied more frequently in those with an increased DFI than those with a decreased DFI (60.7% vs. 27.8%, P<0.01). CONCLUSION: In this longitudinal study, the improvement of AD severity is correlated with the improvement of the patient's QOL, under the age of 3. To improve the family's QOL, we need to find out accompanying factors, such as food allergy, and to support the family accordingly.
Asthma ; Dermatitis ; Dermatitis, Atopic ; Dermatology ; Food Hypersensitivity ; Humans ; Immunoglobulin E ; Longitudinal Studies ; Prospective Studies ; Quality of Life ; Surveys and Questionnaires ; Rhinitis, Allergic, Perennial